David Jackson joins DxS
This article was originally published in Clinica
Executive Summary
UK molecular diagnostics firm DxS has appointed David Jackson vice-president of business development and licensing. Dr Jackson will be based in the US and will be responsible for the company's companion diagnostics and technology licensing divisions. Dr Jackson previously worked for Response Genetics as executive vice-president, and before this was president and chief operating officer of CryoFluor Therapeutics, a company developing a novel cryosurgical platform. He also has "extensive consulting experience in personalised medicine", Manchester-based DxS said.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.